secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001193125-25-297165
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve 2025 equity plan and executive option repricing to $1.50
-----------------------------------------------------------------------------

- 2025 Stock Incentive Plan approved with 30.5M for, 2.9M against.
- CEO René Russo's 2,198,212 options repriced from $5.76 to $1.50.
- CFO Christopher Frankenfield's 848,172 options repriced from $4.67 to $1.50.
- CMO Katarina Luptakova's 225,210 options repriced from $4.10 to $1.50; effective after market close Nov 21.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/0001193125-25-297165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/xlo-20251121.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-297165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer